Home   /  Find a Trial  /  See All Trials HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

see All Trials

Sort by zip code:  

 

Share

Facebook
Twitter

 
16 trials contain the search term(s): "basket"

Basket Study of Entrectinib in Tumors With a NTRK1/2/3, ROS1, or ALK Mutation

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements (NCT02568267)

Summary

Basket studies enroll patients based on the kind of mutations found in their tumors, rather than the type of cancer they have. This is a basket study of entrectinib (RXDX-101) in individuals with solid tumors that have an NTRK1/2/3, ROS1, or ALK gene rearrangement. To be eligible, a breast cancer patient must have a tumor that tests positive for a NTRK1/2/3, ROS1 or ALK rearrangement.


This is a Phase II trial

Treating Advanced Cancer By Choosing Targeted Therapy Based on Tumor's Genetic Makeup

A Basket Study: Targeted Agent and Profiling Utilization Registry (TAPUR) Study (NCT02693535)

Summary

This study is evaluating the safety and effectiveness of using the tumor's genetic alterations to select an FDA-approved targeted therapy for treatment. In this study, the targeted therapy each patient receives will be selected based on their tumor's specific genetic profile. To be eligible, individuals must have no available standard therapy options. This study is enrolling patients with advanced breast and other cancers.

NCI's Exceptional Responder Registry

A Basket Study: Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders (NCT02243592)

Summary

Some cancer patients get better from treatments that didn't work for most patients with their type of tumor. These people are often referred to as exceptional responders. Learning more about the molecular makeup of these patients' tumors may help researchers determine why a treatment worked--and who else might benefit. This study is collecting information about patients with breast and other types of tumors who are considered exceptional responders to their treatment.

  • Participation TimeNumber of visits unavailable
  • Participating research sites
    Research sites: 0 sites total

Two Immunotherapy Drugs for Advanced Breast Cancer

A Basket Study: A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors (COMBO) (NCT02994953)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety, side effects and best dose of the immunotherapy drug NHS-IL12 when it is given in combination with the immunotherapy drug avelumab. NHS-IL12 is an investigational drug. Avelumab (Bavencio) is currently approved for treating certain types of cancers.


This is a Phase I trial

Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial

A Basket Study: An Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial. A Molecular Profile-Based Study in Patients With Advanced Cancer Treated in the Investigational Cancer Therapeutics Program (NCT00851032)

Summary

Molecular profiling allows researchers to identify a tumor's specific mutations and biomarkers. Researchers are trying to see if there is an association between the tumor's molecular profile, how the tumor responds to drugs in phase I trials, and which side effects the patient experiences. To be eligible, participants must be receiving care at the Investigational Cancer Therapeutics department at MD Anderson Cancer Center in Texas.

Prexasertib and Lynparza in Patients With Advanced Breast (and Other) Cancer

A Basket Study: Phase 1 Combination Study of Prexasertib (LY2606368), CHK1 Inhibitor, and Olaparib, PARP Inhibitor, in Patients With Advanced Solid Tumors (NCT03057145)

Summary

To take part in this study, you must have advanced (stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety and effects (good and bad) of using two types of targeted drugs to treat advanced breast cancer. The two drugs being used are Lynparza and prexasertib (LY2606368). Lynparza is approved by the FDA for the treatment of ovarian cancer. Laboratory studies suggest giving prexasertib with Lynparza will make Lynparza more effective. This study is also recruiting patients with other types of cancer.


This is a Phase I trial

BMS-986158 for Advanced Triple Negative Breast (and Other) Cancer

A Basket Study: A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors (NCT02419417)

Summary

To take part in this study, you must have advanced (some stage III) and stage IV triple negative (ER-/PR-/HER2-) breast cancer. This study is investigating whether a new targeted drug for triple negative breast cancer is safe and effective. The new drug being studied is called BMS-986158. It is currently only available in clinical trials. This study also is enrolling patients with other types of advanced cancers.


This is a Phase I-II trial

SY-1365 for Advanced Breast (and Other) Cancer

A Basket Study: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors (NCT03134638)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer. You must have also already had a treatment that your cancer progressed on or did not respond to. This study will help researchers learn the safety and effects (good and bad) of a new targeted drug when it is used to treat advanced or metastatic breast cancer. SY-1365 is the targeted drug used in this study. It is a selective CDK7 inhibitor. This study is also enrolling patients with other types of cancers.


This is a Phase I trial

Targeted Therapy Recommendation Based on Genomic Profiling

A Basket Study: Registry Study for Personalized Cancer Therapy (NCT02508662)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer and have already received a treatment that your cancer progressed on or did not respond to. If you take part in this study, researchers will review your medical records to learn about your tumor's genomic profile. This information will be used to recommend a targeted drug that is FDA-approved for patients who don't have breast cancer but do have tumors with the same genomic profile. This study is also recruiting patients with other types of advanced cancer.

Genomic Profiling to Recommend Treatment for Metastatic Breast (and other solid) Tumors

A Basket study: Tumor Genomic Profiling: A Personalized Medicine Approach (NCT02215928)

Summary

Genomic profiling of a tumor provides information about the specific genetic changes or abnormalities that are helping the cancer grow. Using this information may help doctors determine which treatments will be most effective. In this study, researchers will use genomic profiling to recommend treatments for patients with metastatic breast (and other solid) tumors. This will help them evaluate whether choosing treatment based on genomic profiling is more effective than using the standard treatment. To be eligible, participants must be be receiving breast cancer care at the Stanford Cancer Institute in California.

  • Participation TimeVisits every 6-8 weeks
  • Participating research sites
    Research sites: 0 sites total

Keytruda for Advanced Breast (and Other) Cancers in Women or Men with a BRCA1/2 Mutation

A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability (NCT03428802)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer and have been tested for and found to have a BRCA1 or BRCA2 mutation. This study is investigating the effect of using an immunotherapy drug to treat cancer that has spread outside the breast to nearby tissue or lymph nodes or to other parts of the body. The immunotherapy drug is pembrolizumab (Keytruda®). It is a type of immunotherapy drug called a PD-1 inhibitor. It gets the immune system to go after cancer cells by blocking a protein called programmed cell death (PD-1). It is currently approved to treat certain types of melanoma, head and neck cancer, lung cancer and Hodgkin ly


This is a Phase II trial

Genetic Tumor Profiling to Select Targeted Drug to Treat Advanced Breast Cancer

A Basket Study: Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute (NCT03098576)

Summary

To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer. You must also have had at least one treatment your tumor did not respond to or progressed on. In this study, a sample of your tumor will be analyzed (called molecular profiling) at Cedars-Sinai Medical Center in California to determine which targeted drug could be used as a treatment for your cancer. Molecular profiling is a process that identifies mutations and biomarkers in your tumor's DNA that have FDA-approved matched therapies or are eligible for clinical studies.

BLZ945 Alone or With PDR001 For Metastatic Breast (and Other) Cancer

A Basket Study: A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors (NCT02829723)

Summary

This study has two parts. To enroll in the first part, you must have metastatic breast cancer. To enroll in the second part, you must have metastatic triple negative breast cancer. This study is investigating whether a new type of targeted cancer drug is safe and effective when it is given alone or with an immunotherapy drug. This is the first study to test this new targeted drug in cancer patients. The targeted drug being used in this study is called BLZ945. It targets a receptor called CSF1R that plays a role in tumor growth. Some patients who enroll in this study will also receive an immunotherapy drug called PDR001. This study is also enrolling patients with other types of metastatic cancers.


This is a Phase I-II trial

Analyzing Genetic Mutations Before and After Treatment with Targeted Therapies

A Basket Study: Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy (NCT01775072)

Summary

Most genetic mutations found in cancer cells are not passed down from parents (inherited), but occur when the cells make mistakes when they divide. Most cancers have many mutations. Some of these mutations help drive the tumor's growth, while others are just bystanders. In this study, researchers will analyze the genetic mutations seen in tumor tissue that has previously been collected during a surgery or biopsy and compare these mutations to those found in the patient's DNA. They will also try to identify the mutations that help predict whether the cancer will respond to a certain treatment. And they will look at how genes in the tumor change over time in response to targeted cancer therapies. To be eligible, patients must be receiving ongoing care at Memorial Sloan Kettering Cancer Center.

NCI-MATCH: Choosing the Best Drug for Metastatic Breast (and Other) Cancer

A Basket study: Molecular Analysis for Therapy Choice (MATCH) (NCT02465060)

Summary

Cancer cells grow because they have genetic mistakes (mutations) inside them. Scientists are developing cancer treatments that keep these mistakes from helping the cancer grow. The National Cancer Institute (NCI) started a trial called MATCH (Molecular Analysis for Therapy Choice). If you enroll in NCI-MATCH, the researchers will test your tumor (that's what they mean by molecular analysis) to see what genetic mistakes it contains. The researchers will then see if there is a cancer drug that is a good match for your tumor's genetic mistakes (that's what they mean by therapy choice). To take part in this study, you must have already had one treatment since learning you have metastatic breast cancer.

Molecular Profiling-Based Targeted Therapies for Metastatic Breast (and Other) Cancer

A Basket Study: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT 2) (NCT02152254)

Summary

Molecular profiling of a tumor may identify genetic mutations or biomarkers that suggest the tumor is likely to respond to a currently available targeted therapy. It is not known if choosing metastatic breast (or other types of) cancer based on the tumor's molecular profile is more effective than the current standard of care. All patients who enroll in this study will have molecular profiling performed on a biopsy of their tumor. If there is no mutation or biomarker found, the patient will receive the treatment their doctor determines is the best option. If a mutation or biomarker is found and there is an FDA-approved drug for the tumor type, patients will be offered that treatment. If there is a mutation or biomarker found but no FDA-approved drug that targets it, patients will be randomly assigned to either a targeted therapy or the standard of care.


This is a Phase II trial

  • Participation TimeNumber of visits unavailable
  • Participating research sites
    Research sites: 0 sites total